Genelabs receives patent on DHEA composition, method

By Elaine Rigoli

Tampa, Fla., June 12 - Genelabs Technologies, Inc. was issued U.S. Patent No. 7,045,513 entitled "DHEA Composition and Method," which will expire in August 2022.

The patent claims pharmaceutical formulations of dehydroepiandrosterone, or DHEA, in certain purified polymorphic forms. DHEA is the active ingredient in Prestara, the company's investigational drug for systemic lupus erythematosus, or lupus.

Genelabs' formulation of Prestara is a highly purified synthetic form of DHEA, or prasterone, and the patent covers the specific polymorphic formulation of DHEA used in Genelabs' most recent clinical trials, according to a news release.

The company said it is working with the Food and Drug Administration on the design of a prospective phase 3 clinical trial to evaluate the ability of Prestara to reduce the incidence of flares in lupus patients.

Located in Redwood City, Calif., Genelabs is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.